Module 7: (b) Initial HTN Meds Flashcards
1
Q
ACE Inhibitors (“pril”) -Common Drugs
A
- Lisinopril (Very commonly used)
2. Captopril (Short-acting) (Not used commonly in primary care)
2
Q
ACE Inhibitors (“pril”) -Adverse Effects
A
- Cough (up to 20% of patients)
- HYPERKALEMIA **
- Teratogenic AVOID in pregnancy
- ANGIOEDEMA (Avoid w/ hx of Angioedema
3
Q
ACE Inhibitors (“pril”) -African American Considerations?
A
- AA’s may not have substantial BP lowering w/ ACEi
- AA are 5x greater risk of Angioedema
—Educate Pt to seek ER care if they experience s/s of Angioedema - Research has shown that ACEi and CCB combo had powerful benefits in AA patients
4
Q
ACE Inhibitors (“pril”) -When to Use?
A
- Proteinuric CKD
- HFrEF
- Post-MI
5
Q
ACE Inhibitors (“pril”) -Monitoring?
A
- ACEi can cause INCREASE in serum creatinine
- may be benign or significant - Recheck renal function within 4 weeks. Sometimes Much sooner
Individuals at High risk include:
- Bilateral renal artery stenosis
- Hypertensive nephrosclerosis
- Polycistic kidney dz, HF, and CKD
6
Q
ACE Inhibitors (“pril”) -Baseline Labs to Monitor?
A
- Baseline and periodic BP
- Serum Creatinine
- Electrolytes ESP POTASSIUM for Hyperkalemia
If Patient is on diuretic, start ACE at a lower dose (50%)
7
Q
ACE Inhibitors (“pril”) -When to Discontinue
A
- DC if serum Creatinine increases more than 30% above baseline
- REFER to nephrology
8
Q
ACE Inhibitors (“pril”) -Education?
A
- Start a BP log outpatient
2. Monitor development of dry cough
9
Q
Angiotensin II Receptor Blockers “sartan”
-Common Meds?
A
- Losartan (Most common in Primary care)
10
Q
Angiotensin II Receptor Blockers “sartan”
-Info
A
- No bradykinin-mediated cough like ACEi
- DO NOT combine ARB w/ ACEi
- Considered an alternative to ACEi
11
Q
Angiotensin II Receptor Blockers “sartan”
-Potential Adverse Reactions?
A
- Hyperkalemia (similar to ACEi)
- Teratogenic —avoid in pregnancy
- Can cause changes in renal function including AKI
- Hypotension (More than ACEi)
12
Q
Angiotensin II Receptor Blockers “sartan”
-Benefits
A
- No cough — better than ACEi for Asthma and COPD patients
- Lower incidence of Angioedema
- Enhanced uric acid secretion in gout (Particularly losartan)
13
Q
Angiotensin II Receptor Blockers “sartan”
-Monitoring
A
- BP, Serum Cr, electrolytes (esp. Potassium for Hyperkalemia)
- DC w/ significant deterioration of renal function 30% above baseline and Consult Nephrology
- If patient is on a diuretic, elderly, or volume depleted reduce dose by 50% *
14
Q
CCB
-Two major classes?
A
- Di-hydropyridines (Used more often for HTN)* (Better option for asthma or COPD)*
- Non-dihydropyridines
- CCB’s are effective for BLACK ethnicities, older adults
- Used in angina
15
Q
CCB Di-hydropyridines “pines”
-Exemplars
A
- Amlodipine (Norvasc)(Most commonly prescribed)
Nifedipine (Procardia) - Long-acting agents preferred
- Short acting agents have concern for reflex Tachycardia
16
Q
CCB Di-hydropyridines
-MOA
A
- Di-hydropyridine CCB do NOT affect conduction through the AV node
17
Q
CCB Non-dihydropyridines
-Exemplars & MOA
A
- Diltiazem (Cardizem)
- Verapamil (Calan)
- Affect conduction through the AV node AND have negative chronotropic effects
- Used for rate control in atrial fib